These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3386279)

  • 1. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition.
    Markaverich BM; Roberts RR; Alejandro MA; Johnson GA; Middleditch BS; Clark JH
    J Steroid Biochem; 1988; 30(1-6):71-8. PubMed ID: 3386279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary assessment of luteolin as an affinity ligand for type II estrogen--binding sites in rat uterine nuclear extracts.
    Markaverich BM; Gregory RR
    Steroids; 1993 Jun; 58(6):268-74. PubMed ID: 8212072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naringenin: a weakly estrogenic bioflavonoid that exhibits antiestrogenic activity.
    Ruh MF; Zacharewski T; Connor K; Howell J; Chen I; Safe S
    Biochem Pharmacol; 1995 Oct; 50(9):1485-93. PubMed ID: 7503800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of low dose continuous exposure to estradiol on the estrogen receptor (type I) and nuclear type II sites.
    Markaverich BM; Roberts RR; Alejandro M; Clark JH
    Endocrinology; 1984 Mar; 114(3):814-20. PubMed ID: 6697964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells.
    Reiner GC; Katzenellenbogen BS; Bindal RD; Katzenellenbogen JA
    Cancer Res; 1984 Jun; 44(6):2302-8. PubMed ID: 6547074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear binding of the estrogen receptor: heterogeneity of sites and uterotropic response.
    Clark JH; Markaverich B; Upchurch S; Eriksson H; Hardin JW
    Adv Exp Med Biol; 1979; 117():17-46. PubMed ID: 474276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and characterization of nuclear type II [(3)H]estradiol binding sites from the rat uterus: covalent labeling with [(3)H]luteolin.
    Markaverich BM; Shoulars K; Brown MA
    Steroids; 2001 Sep; 66(9):707-19. PubMed ID: 11546559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An endogenous inhibitor of [3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues.
    Markaverich BM; Roberts RR; Alejandro MA; Clark JH
    Cancer Res; 1984 Apr; 44(4):1515-9. PubMed ID: 6704964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer.
    Caltagirone S; Ranelletti FO; Rinelli A; Maggiano N; Colasante A; Musiani P; Aiello FB; Piantelli M
    Am J Respir Cell Mol Biol; 1997 Jul; 17(1):51-9. PubMed ID: 9224209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrete early changes in cellular subpopulations of rat uterine and anterior pituitary estrogen receptors in response to acute exposure to exogenous estradiol.
    Copland JA; Smanik EJ; Muldoon TG
    J Steroid Biochem; 1987 Jun; 26(6):723-31. PubMed ID: 3613573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary characterization of an endogenous inhibitor of [3H]estradiol binding in rat uterine nuclei.
    Markaverich BM; Roberts RR; Finney RW; Clark JH
    J Biol Chem; 1983 Oct; 258(19):11663-71. PubMed ID: 6619136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of nuclear estrogen-binding sites in the rat uterus: a simple method for the quantitation of type I and type II sites by [3H]estradiol exchange.
    Markaverich BM; Williams M; Upchurch S; Clark JH
    Endocrinology; 1981 Jul; 109(1):62-9. PubMed ID: 7238414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between type I and type II estrogen binding sites in the rat uterus.
    Moses DF; Fridman O; De Nicola AF
    Acta Physiol Pharmacol Latinoam; 1985; 35(4):451-7. PubMed ID: 2940805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a unique population of unfilled estrogen-binding sites associated with the nuclear fraction of immature rat uteri.
    Carlson RA; Gorski J
    Endocrinology; 1980 Jun; 106(6):1776-85. PubMed ID: 7371593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estradiol-stimulated increases in uterine eosinophils and nuclear type II estrogen-binding sites are prevented by pertussis toxin.
    Lyttle CR; Teuscher C; Medlock KL; Sheehan DM
    Endocrinology; 1989 Nov; 125(5):2773-9. PubMed ID: 2792007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites.
    Markaverich BM; Gregory RR; Alejandro MA; Clark JH; Johnson GA; Middleditch BS
    J Biol Chem; 1988 May; 263(15):7203-10. PubMed ID: 3366774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose dependent modulation of receptor dynamics and uterine growth in immature rat by estradiol: importance of an additional nuclear binding at 24 hr for long-term (72 hr) uterine growth.
    Agarwal AK; Durani S; Setty BS
    Endokrinologie; 1982 Jun; 79(2):235-41. PubMed ID: 7128542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine type II estrogen-binding sites are not of eosinophil origin.
    Markaverich BM; Roberts RR; Alejandro MA; Clark JH
    J Biol Chem; 1986 Jan; 261(1):142-6. PubMed ID: 3941067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential response of individual uterine cell types from immature rats treated with estradiol.
    McCormack SA; Glasser SR
    Endocrinology; 1980 May; 106(5):1634-49. PubMed ID: 6153974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.